Oncolytic virotherapy with modified adenoviruses and novel therapeutic targets. - Wikidata - wikimedia - TriplyDB

Oncolytic virotherapy with modified adenoviruses and novel therapeutic targets.

Oncolytic virotherapy with modified adenoviruses and novel therapeutic targets.

http://www.wikidata.org/entity/Q38033591

about

Tumor protein p53 (TP53) testing and Li-Fraumeni syndrome : current status of clinical applications and future directions.The oncolytic virus dl922-947 reduces IL-8/CXCL8 and MCP-1/CCL2 expression and impairs angiogenesis and macrophage infiltration in anaplastic thyroid carcinoma.Homologous recombination-based adenovirus vector system for tumor cell-specific gene delivery.Antitumor efficacy of a recombinant adenovirus encoding endostatin combined with an E1B55KD-deficient adenovirus in gastric cancer cells.A classical PKA inhibitor increases the oncolytic effect of M1 virus via activation of exchange protein directly activated by cAMP 1.Zebrafish: modeling for herpes simplex virus infections.Utilizing adenovirus vectors for gene delivery in cancer.PARP inhibitor olaparib increases the oncolytic activity of dl922-947 in in vitro and in vivo model of anaplastic thyroid carcinoma Model-based rational design of an oncolytic virus with improved therapeutic potential.

P2860

Q34324683-C7AD0EAE-733A-481E-A368-93A0AF5E18CD Q36738884-059DAA6F-CC82-48FF-96D1-114D9648C51B Q37344472-F8872FFB-50FA-4661-A041-C8B4E48DC8B7 Q37370299-D9EE9A95-6FA5-436A-9245-7170DAD288BC Q37565501-ED1F4848-FC39-4539-A364-B51718EB8D50 Q37731157-E98BD15A-CC9D-4B3F-A3C5-3FE9B8D9DA6E Q38176044-9ACF1911-5842-4187-8830-AB679610ED8B Q38964488-15BA3CA5-2A54-4CB7-ACA8-877A797810C6 Q45350759-DF38FF14-37E8-41A5-8B00-EAEA1AB43817

P2860

Oncolytic virotherapy with modified adenoviruses and novel therapeutic targets.

http://www.wikidata.org/entity/Q38033591

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Oncolytic virotherapy with modified adenoviruses and novel therapeutic targets.

@en

type

label

Oncolytic virotherapy with modified adenoviruses and novel therapeutic targets.

@en

prefLabel

Oncolytic virotherapy with modified adenoviruses and novel therapeutic targets.

@en

P1433

Q38033591-527E1186-38E0-4391-8430-276963C66F49

P1476

Q38033591-57B71424-0FEC-49FC-BDB8-8178EBA21823

P2093

Q38033591-1D52D96D-A81B-445B-8A8B-4A64CA9C1CAF

Q38033591-2B0ADC7D-603E-4375-A929-5FE1A422CA20

P2860

Q38033591-0198EBCF-09A5-490A-8C1B-9E549B257F6B

Q38033591-0343C375-7E13-487E-B508-7F85DE158980

Q38033591-03DB5EEB-4239-43AB-B486-D19C4F721894

Q38033591-078EB8A9-9C03-4705-A5A0-37ACD9FDC228

Q38033591-08D19EBC-910C-4CE5-8301-918AC72470F2

Q38033591-11C3CF50-B47C-4A0E-8DC7-E132578B5853

Q38033591-144CC844-2AA1-4FE3-A6B1-B536BD55F15D

Q38033591-14969CAB-3FCF-478B-8603-6DD21B314C60

Q38033591-1517CE6D-F942-469B-A1CC-6CE8C69A549E

Q38033591-179D36DE-0828-403D-A039-69411E4E01C3

P304

Q38033591-78EE8521-FB1F-4929-80E6-3B0D59672C20

P31

Q38033591-0395F07A-A17D-45C3-B29C-83A690D85BEB

P356

Q38033591-1E692FC8-936B-4B17-989F-CFD66C726FCC

P407

Q38033591-671E43D6-4808-4C44-9A6F-7EA5338C2C13

P433

Q38033591-E2D113F6-6D9E-464C-B9B8-EB8AD0070554

P478

Q38033591-53D701A5-F2BC-4325-9F46-201AD8D57BD4

P577

Q38033591-D4D0D887-7EA0-4ECB-B7A3-5BBC2E4CE587

P698

Q38033591-7D668738-B528-4B5F-A5DB-BDA39C6798DB

P921

Q38033591-3834234F-FE1D-425C-9699-7EB197FD58B4

Q38033591-DF250C34-F03C-4EAD-8D7A-B48EDD00A27D

P356

14728222.2012.712962

P1433

Expert Opinion on Therapeutic Targets

P1476

Oncolytic virotherapy with modified adenoviruses and novel therapeutic targets.

@en

P2093

Giuseppe Portella

http://www.w3.org/2001/XMLSchema#string

Gunnel Halldén

http://www.w3.org/2001/XMLSchema#string

P2860

Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes

Autophagy in immunity and inflammation

The autophagy machinery is required to initiate hepatitis C virus replication

The DNA Damage Response: Making It Safe to Play with Knives

The hTERT promoter enhances the antitumor activity of an oncolytic adenovirus under a hypoxic microenvironment

Regulation of the cell cycle and apoptosis by the oncogenes of adenovirus

Cell cycle checkpoints: preventing an identity crisis

Drug penetration in solid tumours

Choreography of the DNA damage response: spatiotemporal relationships among checkpoint and repair proteins

The human membrane cofactor CD46 is a receptor for species B adenovirus serotype 3

P304

945-958

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14728222.2012.712962

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P577

2012-08-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22880939

http://www.w3.org/2001/XMLSchema#string

P921

oncolytic virus